drugset / Trial / NCT03513822
Ketamine's Efficiency in the Treatment of Chronic Pain: Kynurenin Pathway
Phase 3
Unknown
48 enrolled
Redar
Fondation Apicil · collabHopital Lariboisière · collabHospital Ambroise Paré Paris · collabHôpital Raymond Poincaré · collabInstitut National de la Santé Et de la Recherche Médicale, France · collabRecherche Clinique Paris Descartes Necker Cochin Sainte Anne · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The kynurenine pathway is involved in hyperalgesia. This pathway is activated by inflammation. Ketamine would interact with the kynurenine pathway and inflammation. Our working hypotheses are: the clinical effects of ketamine on neuropathic pain are greater in the presence of systemic inflammation and the mechanism of action involves an interaction on the kynurenine pathway. Study design: Interventional randomized placebo-controlled clinical trial. Main goals: 1. To show a better clinical efficacy of ketamine in chronic pain in patients with an inflammatory component. 2. Explore the anti-inflammatory activity of ketamine through the Kynurenine pathway.
Timeline
- Start
- 2018-02-16
- Primary completion
- 2018-10
- Completion
- 2018-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ketamine | Small molecule | 1 mg/kg | Intravenous |
| Comparator | Midazolam | Small molecule | 1 mg | — |